ELB139 Given Orally to Patients With Concurrent Panic Disorder, Challenged by CO2 Inhalation After a Single Dose and One Week of Treatment

NCT00322803 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
24
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

elbion AG